Concepedia

Metabolism of Fostamatinib, the Oral Methylene Phosphate Prodrug of the Spleen Tyrosine Kinase Inhibitor R406 in Humans: Contribution of Hepatic and Gut Bacterial Processes to the Overall Biotransformation

David J. Sweeny, Weiqun Li, Jeffrey Clough, Somasekhar Bhamidipati, Rajinder Singh, Gary Park, Muhammad Baluom, Elliott B. Grossbard, David Lau

Drug Metabolism and Disposition · 2010 · 89 citations · 17 references

References

17

R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation

Sylvia Braselmann, Vanessa Taylor, H. Zhao et al. · Journal of Pharmacology and Experimental Therapeutics · 2006 · 511 citations

Life Sciences, Immunology, Pharmacology +17

Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve‐week, randomized, placebo‐controlled trial

Michael E. Weinblatt, Arthur Kavanaugh, Rubén Burgos‐Vargas et al. · Arthritis & Rheumatism · 2008 · 336 citations

Medicine, Immunology, Pharmacology +12

Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk

Anna J. Podolanczuk, Alan H. Lazarus, Andrew R. Crow et al. · Blood · 2008 · 272 citations · Full text

Medicine, Hematology, Pharmacology +7

Intestinal Bacterial Communities That Produce Active Estrogen-Like Compounds Enterodiol and Enterolactone in Humans

Thomas Clavel, Gemma Henderson, Carl-Alfred Alpert et al. · Applied and Environmental Microbiology · 2005 · 212 citations · Full text

Life Sciences, Microbiology, Microbial Ecology +8

Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor

Polly Pine, Betty Chang, Nathan Schoettler et al. · Clinical Immunology · 2007 · 207 citations

Medicine, Immunology, Pharmacotherapy +16